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from viral mediated proof of concept to development of a protein
therapeutic, we determined in rats and rabbits the intraarticular
pharmacokinetics of sFlt01, a VEGF neutralizing Fc fusion protein,
and subsequently the feasibility of sustained release formulation
for prolonging residence time in the joint at or above therapeu-
tic levels for 30∼90 days. N-methyl pyrollidone/poly(lactic acid)
(NMP/PLA) depot is considered here as the formulation strategy.
Methods: Iodinated sFlt01 PK in rat: 65ug 125I-sFlt01 was intraar-
ticularly administered to rat knees 4 weeks after meniscectomy
surgery. Radioactivity of the knee joints was measured at sacriﬁce
1, 6, 24, 72, and 144hrs post injection.
sFlt01 PK in rabbit: 150ug sFlt01 was intraarticularly administered
to rabbit knee 4 weeks after ACL surgery. Rabbits were sacriﬁced
at 6hr, 8hr, 24hr, 18hr, and 48hr post injection. sFlt01 level in
serum, urine, synovial ﬂuid, articular cartilage and synovium was
quantiﬁed by ELISA.
sFlt01 sustained release: NMP/PLA depots were formed by dis-
solving PLA in NMP in a 40:60 w:w ratio. Lyophilized sFlt01 was
added to a concentration of 0.8-1.7 w% and dispersed by son-
ication. Depots were formed by pipetting ∼10ug of material into
PBS, allowing the NMP to dissipate and the depot to solidify. In
vitro release was conducted under physiologic conditions (PBS
+ Tween 20, 37°C). Drug release was quantiﬁed by BCA. VEGF
binding activity was assessed by Biacore and ELISA.
Results: Iodinated sFlt01 PK in rats: The knee joint terminal half
life of sFlt01 is estimated to be 11 hours in OA rats. There is a
very small shift in terminal elimination half life of sFlt01 in joint
between OA rats and non-OA rats.
sFlt01 PK in rabbits: In general, terminal elimination half life of
sFlt01 in joint synovial ﬂuid, synovium and cartilage is very similar
in OA and non-OA groups. Exposure in joint synovial ﬂuid, syn-
ovium, and cartilage is higher in non-OA group than that in OA
group. Systemic exposure in the serum is comparable between
OA and non-OA animals. Absorption of sFlt01 into systemic cir-
culation appears to be very slow. sFlt01 is not detected in urine,
kidney, heart, liver and lung.
sFlt01 sustained release: The NMP/PLA depot showed a nonlinear
release pattern with ∼15% released in 26 days. sFlt01 released
from NMP/PLA depots demonstrated the ability to neutralize VEGF,
as determined by an ELISA assay. Biacore studies showed that
sFlt01 released from NMP-PLA depots lost some capacity to bind
to protein A, indicating modiﬁcation to the Fc portion, but that
captured sFlt01still strongly bound VEGF.
t1/2 (hrs) Synovium Cartilage Synovial Fluid Serum
OA 9.84 7.02 7.77 66.5
Non-OA 9.42 6.19 10.3 71.5
Conclusions: Joint half-life of sFlt01 is as short as hours, sug-
gesting that sustained release formulation is necessary to prolong
sFlt01 residence time in the joint. NMP/PLA depots were shown
to deliver sFlt01 for ∼30 days. New formulations will be in need to
further prolong release, characterize late stage burst and sFlt01
alterations, and to test pharmacokinetics in vivo.
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Purpose: There are no proven therapies that modify the structural
changes in osteoarthritis (OA). Preclinical data suggests that
intra-articular recombinant human Osteogenic Protein-1 (OP-1)
has reparative effects on cartilage, as well as on symptoms of joint
pain. The objective of this study was to determine the safety and
tolerability as well as dose-limiting toxicity and maximal tolerated
dose of intra-articular OP-1. The secondary objectives were to
determine the symptomatic responses through 24 weeks.
Methods: This was a Phase 1, double-blind, randomized, multi-
center, placebo-controlled, single-dose escalation safety study
consisting of 4 dosing cohorts in participants with knee OA. Each
cohort was to consist of 8 treated subjects, with treatment allo-
cation in a 3:1 active (of intra-articular OP-1 (also called BMP-7))
to placebo ratio. Eligible subjects were persons with symptomatic
radiographic knee OA aged over 40 years. The primary objec-
tive of this study was to determine the safety and tolerability
including laboratory assessments, immunogenicity data and ra-
diographic assessments. Secondary objectives were to determine
the proportion of subjects with a 20%, 50%, and 70% improve-
ment in the WOMAC pain and function subscales at 4, 8, 12, and
24 weeks. Other secondary outcomes included the change from
baseline to 4, 8, 12, and 24 weeks for the subscales of the Knee
and Osteoarthritis Outcome Score (KOOS) survey, patient global,
physician global, quality of life from the SF-36 and the OARSI
responder criteria.
Results: The mean age of participants was 60 years and 73%
were female. All 33 subjects who were enrolled completed the
study, most adverse events were mild or moderate and were
similar in placebo and OP-1 groups. The 1mg OP-1 group showed
a higher frequency of injection site pain and there was no ectopic
bone formation seen on plain x-rays. Most subjects in both the
OP-1 and placebo groups experienced a 20% improvement in
pain and by 12 Weeks, the OP-1 group was similar to placebo. In
the participants who received 0.1mg and 0.3mg OP-1, there was
a trend toward greater symptomatic improvement than placebo.
The other secondary endpoints showed similar trends including
the OARSI responder criteria for which the OP-1 groups had more
responders than placebo (see table).
Number (%) of 0.03mg 0.1mg 0.3mg 1mg All Placebo
Responders (N=7) (N=6) (N=6) (N=6) (N=25) (N=8)
Week 4 3 (42.9%) 4 (66.7%) 1 (16.7%) 2 (33.3%) 10 (40%) 1 (12.5%)
Week 8 3 (42.9%) 4 (66.7%) 2 (33.3%) 2 (33.3%) 11 (44%) 0 (0%)
Week 12 1 (14.3%) 4 (66.7%) 2 (33.3%) 1 (16.7%) 8 (32%) 1 (12.5%)
Week 24 1 (14.3%) 5 (83.3%) 2 (33.3%) 1 (20%) 9 (37.5%) 1 (12.5%)
Conclusions: There was no dose limiting toxicity identiﬁed in
this study. The overall trend for OP-1 symptom response was
better than placebo with the 0.1 and 0.3 mg groups. The bell
shaped dose response curve is consistent with pharmacodynamic
studies in pre-clinical models. This symptom response, together
with the lack of dose limiting toxicity provide further support
for the continued development of this product for treatment of
osteoarthritis.
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Purpose: Hyaluronic acid (HA) injections are widely used to treat
knee osteoarthritis (OA). Current evidence on their efﬁcacy, based
on individual trials and meta-analyses, is inconsistent. In the face
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of this disparity, we aimed to re-examine the clinical usefulness of
HA products, from the perspective of their relative efﬁcacy when
compared against Corticosteroid (CS) injections, a widely used
intervention which clinicians have considerable familiarity with and
are widely recommended in consensus statements. Additionally,
we sought to determine how their relative efﬁcacy performs over
time, as prior trials suggest that they have different response
trajectories.
Methods: We searched Medline, EMBASE, CINAHL, BIOSIS and
Cochrane database from inception to February 2009 for human
randomized clinical trials comparing HA with CS for knee OA. We
also hand searched review articles, manuscripts and supplements
from medical journals and contacted authors for unpublished data.
Two reviewers (RRB, NSN) independently performed data extrac-
tion and scored each trial using the Jadad scale. We computed
relative effect sizes for pain change from baseline to weeks (wk)
2, 4, 8, 12 and 26 for each study using Hedges’ g statistic.
Effect sizes were pooled using a random effects model. Sensi-
tivity analyses were performed among trial subsets that reported
intent-to-treat (ITT) analysis, blinding methodology and those that
compared Hyalgan® with Depo-Medrol®.
Results: The 7 eligible trials included 606 participants with an age
range of 49 to 72 years. They included HA (n = 312; 101 men, 211
women) and CS (n = 294; 99 men, 195 women). Jadad quality
scores ranged from 2 to 4 and were published between 1987
and 2004. The relative effect size favored CS at wk 2 -0.39 (95%
conﬁdence interval -0.65, -0.12) and suggested equal efﬁcacy at
wk 4 (-0.01; -0.23, 0.21). At wk 8 (0.22; -0.05, 0.49), wk 12 (0.35;
0.03, 0.66) and wk 26 (0.39; 0.18, 0.59) it favored HA.
The results were consistent when we conﬁned the pooled analysis
to the 5 trials that reported ITT (Table 1). The relative effect size
favored CS at wk 2 (-0.39; -0.65, -0.12) and suggested equal
efﬁcacy at wk 4 (-0.004; -0.30, 0.30). At wk 8 (0.22; -0.05, 0.49),
wk 12 (0.27; -0.16, 0.69) and wk 26 (0.38; 0.15, 0.60) it favored
HA. Results were consistent when we conﬁned the pooled analysis
to the 4 trials that reported blinding methodology. It favored CS
at wk 2 (-0.36; -0.82, 0.10) and suggested equal efﬁcacy at wk 4
(-0.11; -0.42, 0.21) and wk 8 (0.08; -0.27, 0.43). At wk 12 (0.27;
-0.16, 0.70) and wk 26 (0.37; 0.16, 0.59) it favored HA. When
we conﬁned the pooled analysis to the 4 trials that compared
Hyalgan® with Depo-Medrol®, it favored CS at wk 2 (-0.43; -0.79,
-0.08) and suggested equal efﬁcacy at wk 4 (0.01; -0.43, 0.45). At
wk 8 (0.21; -0.18, 0.60) it favored HA.
Table 1. Pooled relative effect sizes (95% CI)
Primary Analysis ITT Analysis Blinding
7 trials 5 trials 4 trials
Wk 2 -0.39 (-0.65, -0.12) -0.39 (-0.65, -0.12) -0.36 (-0.82, 0.10)
Wk 4 -0.01 (-0.23, 0.21) -0.004 (-0.30, 0.30) -0.11 (-0.42, 0.21)
Wk 8 0.22 (-0.05, 0.49) 0.22 (-0.05, 0.49) 0.08 (-0.27, 0.43)
Wk 12 0.35 (0.03, 0.66) 0.27 (-0.16, 0.69) 0.27 (-0.16, 0.70)
Wk 26 0.39 (0.18, 0.59) 0.38 (0.15, 0.60) 0.37 (0.16, 0.59)
Figure 1. Graph showing relative effect size at each time point (95% CI).
Conclusions: This meta-analysis shows a pattern of relative efﬁ-
cacy that varies over time. In the short term (up to 4 weeks), CS
appears to be more effective for pain. By wk 4 the two approaches
have equal efﬁcacy, but by wk 8 and beyond HA products have
greater relative effects (Fig 1). The possible limitations of our anal-
ysis would be the inﬂuence of methodological issues among the
individual trials and the use of different formulations and doses
of CS. We addressed these issues by performing several sensi-
tivity analyses using these variables. Awareness of this pattern
of response will be useful to the clinician when formulating a
therapeutic plan for patients with knee OA.
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Purpose: To compare the efﬁcacy and safety of ultrasound-guided
local injections of hyaluronic acid (HA) (Suplasyn® 500-1000
kDa) and betamethasone in the management of patients with
osteoarthritis of the thumb.
Methods: Patients of both sexes, aged > 40 years, diagnosed
with osteoarthritis of the thumb (Kellgren-Lawrence grade II and III)
according to the ACR criteria were included in the study. Patients
were randomized (1:1) to ultrasound-guided local treatment with
HA or betamethasone. A total of three local injections of active
medication were scheduled at 7-day intervals. Paracetamol, 2
g/day, was allowed as rescue medication. Assessments performed
at baseline and at 7, 14, 30, 90 and 180 days included pain
evaluation with a 100-mm visual analogue scale (VAS), Dreiser’s
functional index (score 0-30), and global evaluation of efﬁcacy
by the investigator and the patient. The Student’s t test or the
Mann-Whitney U test for continuous variables and the chi-square
test for categorical variables were used.
Results: In both study groups (40 patients in each group), VAS
scores at the follow-up assessments showed a signiﬁcant de-
crease as compared with baseline, but differences between the
groups of HA and betamethasone were not statistically signiﬁ-
cant. In both groups, maximal pain relief occurred at 30 days.
Scores of the Dreiser’s functional index decreased signiﬁcantly in
both groups as compared with baseline, but at 90 days in which
maximal improvement was also seen, HA-treated patients scored
5.50 and betamethasone-treated patients scored 10.0 (P = 0.04).
A trend towards a greater clinical improvement in the HA group
compared with the betamethasone group was also recorded at
90 days in the patients’ assessment of efﬁcacy (P = 0.08). Local
adverse events did not occur.
Conclusions: Ultrasound-guided local injections of HA and be-
tamethasone were both effective and well tolerated for the man-
agement of patients with osteoarthritis of the thumb, although HA
seemed to provide better functional beneﬁts than betamethasone.
